Coherus Oncology files to sell up to $50 million in stock through Leerink Partners

Coherus Oncology, Inc. filed a prospectus supplement dated August 28, 2026 covering up to $50,000,000 in common stock sales through an at-the-market program. The company entered into a sales agreement with Leerink Partners LLC dated August 28, 2026, relating to shares of common stock offered under this prospectus supplement and an accompanying prospectus.¹

Coherus common stock trades on the Nasdaq Global Market under the symbol CHRS, and closed at $1.46 per share on August 27, 2026.¹ Leerink Partners will be compensated up to 3.0% of gross proceeds from any shares sold under the agreement.¹ Coherus has also agreed to reimburse Leerink Partners up to $100,000 in outside legal expenses, and estimates total offering expenses, excluding Leerink's commissions, at approximately $450,000.¹

The company describes itself as a commercial-stage oncology business built around its approved drug LOQTORZI, an antibody the filing identifies by its generic name toripalimab-tpzi, along with two clinical-stage candidates aimed at several cancer types including liver, prostate, head and neck, and colorectal cancers. Coherus said its strategy is to grow LOQTORZI sales in nasopharyngeal cancer while advancing its two pipeline candidates in combination with LOQTORZI or other agents, and it holds global rights to both clinical-stage candidates with plans for ex-U.S. licensing as data supports such deals.¹

Coherus intends to use net proceeds from the offering for general corporate purposes.¹ The filing also notes the company has a Loan and Security Agreement with Innovatus Life Sciences Lending Fund I, LP as collateral agent, which includes covenants requiring the company to maintain certain cash levels.¹ No fixed timeline or minimum share sales are specified for the ATM program.